These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34707600)
1. Rapid Identification of the Tumor-Specific Reactive TIL Repertoire Draghi A; Chamberlain CA; Khan S; Papp K; Lauss M; Soraggi S; Radic HD; Presti M; Harbst K; Gokuldass A; Kverneland A; Nielsen M; Westergaard MCW; Andersen MH; Csabai I; Jönsson G; Szallasi Z; Svane IM; Donia M Front Immunol; 2021; 12():705422. PubMed ID: 34707600 [TBL] [Abstract][Full Text] [Related]
2. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. Eiva MA; Omran DK; Chacon JA; Powell DJ Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280 [TBL] [Abstract][Full Text] [Related]
3. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. Williams JB; Horton BL; Zheng Y; Duan Y; Powell JD; Gajewski TF J Exp Med; 2017 Feb; 214(2):381-400. PubMed ID: 28115575 [TBL] [Abstract][Full Text] [Related]
4. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641 [TBL] [Abstract][Full Text] [Related]
5. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8 Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502 [TBL] [Abstract][Full Text] [Related]
6. Functional Heterogeneity of CD4 Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P Front Immunol; 2018; 9():2654. PubMed ID: 30505306 [TBL] [Abstract][Full Text] [Related]
7. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077 [TBL] [Abstract][Full Text] [Related]
8. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318 [No Abstract] [Full Text] [Related]
9. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772 [TBL] [Abstract][Full Text] [Related]
10. 4-1BB Agonist Focuses CD8 Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567 [No Abstract] [Full Text] [Related]
16. Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Pilch H; Höhn H; Neukirch C; Freitag K; Knapstein PG; Tanner B; Maeurer MJ Clin Diagn Lab Immunol; 2002 Mar; 9(2):267-78. PubMed ID: 11874862 [TBL] [Abstract][Full Text] [Related]
17. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Ye Q; Song DG; Poussin M; Yamamoto T; Best A; Li C; Coukos G; Powell DJ Clin Cancer Res; 2014 Jan; 20(1):44-55. PubMed ID: 24045181 [TBL] [Abstract][Full Text] [Related]
18. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565 [TBL] [Abstract][Full Text] [Related]
19. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232 [TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. Wen T; Bukczynski J; Watts TH J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]